Search
Roflumilast Topical (Zoryve)
Indications:
- treatment of ezcema (FDA-approved)
- treatment of plaque psoriasis
- treatment of seborrheic dermatitis
Dosage:
- 0.15% cream for treatment of eczema
- 0.3% cream for treatment of plaque psoriasis
- 0.3% foam for treatment of seborrheic dermatitis
- 0.3% foam once daily for scalp & body psoriasis [2]
Adverse effects:
- headache (2.9%)
- nausea (1.9%), vomiting (1.5%)
- diarrhea (1.5%)
- application site pain (1.5%)
Mechanism of action:
- see roflumilast
General
roflumilast (Daliresp)
topical agent
References
- Brunk D
Roflumilast Cream 0.15% Approved for Eczema in Patients Aged 6 or Older.
Medscape, July 10, 2024
https://www.medscape.com/viewarticle/roflumilast-cream-approved-eczema-patients-2024a1000cpx
- Gooderham MJ, Alonso-Llamazares J, Bagel J et al
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3
Randomized Clinical Trial.
JAMA Dermatol. 2025 May 7.
PMID: 40332898
https://jamanetwork.com/journals/jamadermatology/fullarticle/2833460